• Principal Investigator
  • Male

Prof. dr. R.W. Sanders

Position: Professor
Main activities: Research
Specialisation: Virology, in particular Experimental Vaccinology
foto R.W. Sanders is one of the AMC Principal Investigators
Focus of research:

HIV vaccine research

AMC themes: Infection & Immunity
Departments: Medical Microbiology
de Taeye SW. Stabilization of HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. S.l.: s.n.; 2017. 288p. ISBN 978-94-6299-541-3 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Berkhout B, Sanders RW; copromotor(s): )
de Vries RP, Peng W, Grant OC, Thompson AJ, Zhu X, Bouwman KM, de la Pena ATT, van Breemen MJ, Ambepitiya Wickramasinghe IN, de Haan CAM, Yu W, McBride R, Sanders RW, Woods RJ, Verheije MH, Wilson IA, Paulson JC, Three mutations switch H7N9 influenza to human-type receptor specificity. PLOS PATHOG 2017;13 (6):e1006390 [PubMed]
de Vries RP, Tzarum N, Peng W, Thompson AJ, Ambepitiya Wickramasinghe IN, de la Pena ATT, van Breemen MJ, Bouwman KM, Zhu X, McBride R, Yu W, Sanders RW, Verheije MH, Wilson IA, Paulson JC, A single mutation in Taiwanese H6N1 influenza hemagglutinin switches binding to human-type receptors. EMBO MOL MED 2017;9 (9):1314-1325 [PubMed]
dey AK, Cupo A, Ozorowski G, Sharma VK, Behrens AJ, Go EP, Ketas TJ, Yasmeen A, Klasse PJ, Sayeed E, Desaire H, Crispin M, Wilson IA, Sanders RW, Hassell T, Ward A, Moore JP, cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. BIOTECHNOL BIOENG 2017;ahead of print [PubMed]
Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H, Cesar Lorenzi JC, Halper-Stromberg A, Toth I, Piechocka-Trocha A, Gristick HB, van Gils MJ, Sanders RW, Wang LX, Seaman MS, Burton DR, Gazumyan A, Walker BD, West AP Jr, Bjorkman PJ, Nussenzweig MC, Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. SCI TRANSL MED 2017;9 (373):eaal2144 [PubMed]
Mayer CT, Gazumyan A, Kara EE, Gitlin AD, Golijanin J, Viant C, Pai J, Oliveira TY, Wang Q, Escolano A, Medina-Ramirez M, Sanders RW, Nussenzweig MC, The microanatomic segregation of selection by apoptosis in the germinal center. SCIENCE 2017;358 (6360):193-+ [PubMed]
Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens AJ, Ozorowski G, van den Kerkhof TLGM, Freund NT, Dosenovic P, Hua Y, Gitlin AD, Cupo A, van der Woude P, Golabek M, Sliepen K, Blane T, Kootstra N, van Breemen MJ, Pritchard LK, Stanfield RL, Crispin M, Ward AB, Stamatatos L, Klasse PJ, Moore JP, Nemazee D, Nussenzweig MC, Wilson IA, Sanders RW, Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J EXP MED 2017;214 (9):2573-2590 [PubMed]
Medina-Ramírez M, Sanders RW, Sattentau QJ, Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. CURR OPIN HIV AIDS 2017;12 (3):241-249 [PubMed]
Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R, Boopathy AV, Carnathan DG, Chandrashekar A, Cirelli KM, Cottrell CA, Eroshkin AM, Guenaga J, Kaushik K, Kulp DW, Liu J, McCoy LE, Oom AL, Ozorowski G, Post KW, Sharma SK, Steichen JM, de Taeye SW, Tokatlian T, Torrents de la Peña A, Butera ST, LaBranche CC, Montefiori DC, Silvestri G, Wilson IA, Irvine DJ, Sanders RW, Schief WR, Ward AB, Wyatt RT, Barouch DH, Crotty S, Burton DR, Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. IMMUNITY 2017;46 (6):1073-1088.e6 [PubMed]
Ringe RP, Ozorowski G, Rantalainen K, Struwe WB, Matthews K, Torres JL, Yasmeen A, Cottrell CA, Ketas TJ, LaBranche CC, Montefiori DC, Cupo A, Crispin M, Wilson IA, Ward AB, Sanders RW, Klasse PJ, Moore JP, Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. J VIROL 2017;91 (15):UNSP e00677-17 [PubMed]
Ringe RP, Ozorowski G, Yasmeen A, Cupo A, Cruz Portillo VM, Pugach P, Golabek M, Rantalainen K, Holden LG, Cottrell CA, Wilson IA, Sanders RW, Ward AB, Klasse PJ, Moore JP, Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. J VIROL 2017;91 (12):UNSP e00264-17 [PubMed]
Sanders RW, Moore JP, Native-like Env trimers as a platform for HIV-1 vaccine design. IMMUNOL REV 2017;275 (1):161-182 [PubMed]
Saunders KO, Nicely NI, Wiehe K, Bonsignori M, Meyerhoff RR, Parks R, Walkowicz WE, Aussedat B, Wu NR, Cai F, Vohra Y, Park PK, Eaton A, Go EP, Sutherland LL, Scearce RM, Barouch DH, Zhang R, Von Holle T, Overman RG, Anasti K, Sanders RW, Moody MA, Kepler TB, Korber B, Desaire H, Santra S, Letvin NL, Nabel GJ, Montefiori DC, Tomaras GD, Liao HX, Alam SM, Danishefsky SJ, Haynes BF, Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. CELL REP 2017;18 (9):2175-2188 [PubMed]
Snapp EL, McCaul N, Quandte M, Cabartova Z, Bontjer I, Källgren C, Nilsson I, Land A, von Heijne G, Sanders RW, Braakman I, Structure and topology around the cleavage site regulate post-translational cleavage of the HIV-1 gp160 signal peptide. ELIFE 2017;6:e26067 [PubMed]
Sullivan JT, Sulli C, Nilo A, Yasmeen A, Ozorowski G, Sanders RW, Ward AB, Klasse PJ, Moore JP, Doranz BJ, High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. J VIROL 2017;91 (22):UNSP e00862-17 [PubMed]
Torrents de la Peña A, Julien JP, de Taeye SW, Garces F, Guttman M, Ozorowski G, Pritchard LK, Behrens AJ, Go EP, Burger JA, Schermer EE, Sliepen K, Ketas TJ, Pugach P, Yasmeen A, Cottrell CA, Torres JL, Vavourakis CD, van Gils MJ, Labranche C, Montefiori DC, Desaire H, Crispin M, Klasse PJ, Lee KK, Moore JP, Ward AB, Wilson IA, Sanders RW, Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. CELL REP 2017;20 (8):1805-1817 [PubMed]
van Gils MJ, Sanders RW, Opposites attract in bispecific antibody engineering. J BIOL CHEM 2017;292 (35):14718-14719 [PubMed]
van Gils MJ, van den Kerkhof TLGM, Ozorowski G, Cottrell CA, Sok D, Pauthner M, Pallesen J, de Val N, Yasmeen A, de Taeye SW, Schorcht A, Gumbs S, Johanna I, Saye-Francisco K, Liang CH, Landais E, Nie X, Pritchard LK, Crispin M, Kelsoe G, Wilson IA, Schuitemaker H, Klasse PJ, Moore JP, Burton DR, Ward AB, Sanders RW, An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. NAT MICROBIOL 2017;2 (2):16199 [PubMed]
Behrens AJ, Vasiljevic S, Pritchard LK, Harvey DJ, Andev RS, Krumm SA, Struwe WB, Cupo A, Kumar A, Zitzmann N, Seabright GE, Kramer HB, Spencer DIR, Royle L, Lee JH, Klasse PJ, Burton DR, Wilson IA, Ward AB, Sanders RW, Moore JP, Doores KJ, Crispin M, Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. CELL REP 2016;14 (11):2695-2706 [PubMed]
Cornelissen M, Euler Z, van den Kerkhof TLGM, van Gils MJ, Boeser-Nunnink BDM, Kootstra NA, Zorgdrager F, Schuitemaker H, Prins JM, Sanders RW, van der Kuyl AC, The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype. AIDS RES HUM RETROV 2016;32 (10-11):1135-1142 [PubMed]
Derking R. Antigenic structure of the HIV-1 envelope glycoprotein trimer. S.l.: s.n.; 2016. 221p. ISBN 978-94-6299-426-3 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Berkhout B; copromotor(s): Sanders RW)
de Taeye SW, Moore JP, Sanders RW, HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. TRENDS IMMUNOL 2016;37 (3):221-232 [PubMed]
Eggink D, de Taeye SW, Bontjer I, Klasse PJ, Langedijk JPM, Berkhout B, Sanders RW, HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike. J VIROL 2016;90 (23):10587-10599 [PubMed]
Havenar-Daughton C, Carnathan DG, Torrents de la Peña A, Pauthner M, Briney B, Reiss SM, Wood JS, Kaushik K, van Gils MJ, Rosales SL, van der Woude P, Locci M, Le KM, de Taeye SW, Sok D, Mohammed AUR, Huang J, Gumber S, Garcia A, Kasturi SP, Pulendran B, Moore JP, Ahmed R, Seumois G, Burton DR, Sanders RW, Silvestri G, Crotty S, Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. CELL REP 2016;17 (9):2195-2209 [PubMed]
Havenar-Daughton C, Reiss SM, Carnathan DG, Wu JE, Kendric K, Torrents de la Peña A, Kasturi SP, Dan JM, Bothwell M, Sanders RW, Pulendran B, Silvestri G, Crotty S, Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique. J IMMUNOL 2016;197 (3):994-1002 [PubMed]
Klasse PJ, LaBranche CC, Ketas TJ, Ozorowski G, Cupo A, Pugach P, Ringe RP, Golabek M, van Gils MJ, Guttman M, Lee KK, Wilson IA, Butera ST, Ward AB, Montefiori DC, Sanders RW, Moore JP, Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. PLOS PATHOG 2016;12 (9):e1005864 [PubMed]
McCoy LE, van Gils MJ, Ozorowski G, Messmer T, Briney B, Voss JE, Kulp DW, Macauley MS, Sok D, Pauthner M, Menis S, Cottrell CA, Torres JL, Hsueh J, Schief WR, Wilson IA, Ward AB, Sanders RW, Burton DR, Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. CELL REP 2016;16 (9):2327-2338 [PubMed]
Sanders RW, Wilson IA, Moore JP, HiV's ACHILLES' HEEL. SCI AM 2016;315 (6):50-55
Schiffner T, de Val N, Russell RA, de Taeye SW, de la Peña AT, Ozorowski G, Kim HJ, Nieusma T, Brod F, Cupo A, Sanders RW, Moore JP, Ward AB, Sattentau QJ, Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. J VIROL 2016;90 (2):813-828 [PubMed]
Sliepen K. HIV-1 envelope trimer fusion proteins and their applications. S.l.: s.n.; 2016. 183p. ISBN 978-94-6299-359-4 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Berkhout B; copromotor(s): Sanders RW)
Sliepen K, Sanders RW, HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. EXPERT REV VACCINES 2016;15 (3):349-365 [PubMed]
Tam HH, Melo MB, Kang M, Pelet JM, Ruda VM, Foley MH, Hu JK, Kumari S, Crampton J, Baldeon AD, Sanders RW, Moore JP, Crotty S, Langer R, Anderson DG, Chakraborty AK, Irvine DJ, Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. P NATL ACAD SCI USA 2016;113 (43):E6639-E6648 [PubMed]
van den Kerkhof TLGM. HIV-1 vaccine design: Learning from natural infection. S.l.: s.n.; 2016. 301p. ISBN 978-94-6299-320-4 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker J; copromotor(s): Sanders RW)
van den Kerkhof TLGM, de Taeye SW, Boeser-Nunnink BD, Burton DR, Kootstra NA, Schuitemaker H, Sanders RW, van Gils MJ, HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. RETROVIROLOGY 2016;13 (1):48 [PubMed]
van den Kerkhof TLGM, van Gils MJ, Boeser-Nunnink BD, Burger JA, Schuitemaker H, Sanders RW, Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies. AIDS 2016;30 (14):2179-2184 [PubMed]
Alexander MR, Ringe R, Sanders RW, Voss JE, Moore JP, Klasse PJ, What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?. J VIROL 2015;89 (11):5981-5995 [PubMed]
Alexander MR, Sanders RW, Moore JP, Klasse PJ, Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein. AIDS RES HUM RETROV 2015;31 (11):1160-1165 [PubMed]
Carrillo J, Molinos-Albert LM, Rodríguez de la Concepción ML, Marfil S, García E, Derking R, Sanders RW, Clotet B, Blanco J, Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals. PLOS ONE 2015;10 (3):e0120648 [PubMed]
Derking R, Ozorowski G, Sliepen K, Yasmeen A, Cupo A, Torres JL, Julien JP, Lee JH, van Montfort T, de Taeye SW, Connors M, Burton DR, Wilson IA, Klasse PJ, Ward AB, Moore JP, Sanders RW, Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLOS PATHOG 2015;11 (3):e1004767 [PubMed]
de Taeye SW, Ozorowski G, Torrents de la Peña A, Guttman M, Julien JP, van den Kerkhof TLGM, Burger JA, Pritchard LK, Pugach P, Yasmeen A, Crampton J, Hu J, Bontjer I, Torres JL, Arendt H, DeStefano J, Koff WC, Schuitemaker H, Eggink D, Berkhout B, Dean H, Labranche C, Crotty S, Crispin M, Montefiori DC, Klasse PJ, Lee KK, Moore JP, Wilson IA, Ward AB, Sanders RW, Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. CELL 2015;163 (7):1702-1715 [PubMed]
Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, McGuire AT, Kulp DW, Oliveira T, Scharf L, Pietzsch J, Gray MD, Cupo A, van Gils MJ, Yao KH, Liu C, Gazumyan A, Seaman MS, Björkman PJ, Sanders RW, Moore JP, Stamatatos L, Schief WR, Nussenzweig MC, Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. CELL 2015;161 (7):1505-1515 [PubMed]
Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A, Sanders RW, Moore JP, Bjorkman PJ, Seaman MS, Walker BD, Klein F, Nussenzweig MC, A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLOS PATHOG 2015;11 (10):e1005238 [PubMed]
Garces F, Lee JH, de Val N, de la Pena AT, Kong L, Puchades C, Hua Y, Stanfield RL, Burton DR, Moore JP, Sanders RW, Ward AB, Wilson IA, Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. IMMUNITY 2015;43 (6):1053-1063 [PubMed]
Guttman M, Cupo A, Julien JP, Sanders RW, Wilson IA, Moore JP, Lee KK, Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. NAT COMMUN 2015;6:6144 [PubMed]
Hu JK, Crampton JC, Cupo A, Ketas T, van Gils MJ, Sliepen K, de Taeye SW, Sok D, Ozorowski G, Deresa I, Stanfield R, Ward AB, Burton DR, Klasse PJ, Sanders RW, Moore JP, Crotty S, Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. J VIROL 2015;89 (20):10383-10398 [PubMed]
Julien JP, Lee JH, Ozorowski G, Hua Y, Torrents de la Peña A, de Taeye SW, Nieusma T, Cupo A, Yasmeen A, Golabek M, Pugach P, Klasse PJ, Moore JP, Sanders RW, Ward AB, Wilson IA, Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. P NATL ACAD SCI USA 2015;112 (38):11947-11952 [PubMed]
Kong L, Torrents de la Peña A, Deller MC, Garces F, Sliepen K, Hua Y, Stanfield RL, Sanders RW, Wilson IA, Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. ACTA CRYSTALLOGR D 2015;71 (Part 10):2099-2108 [PubMed]
Lee JH, Leaman DP, Kim AS, Torrents de la Peña A, Sliepen K, Yasmeen A, Derking R, Ramos A, de Taeye SW, Ozorowski G, Klein F, Burton DR, Nussenzweig MC, Poignard P, Moore JP, Klasse PJ, Sanders RW, Zwick MB, Wilson IA, Ward AB, Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. NAT COMMUN 2015;6:8167 [PubMed]
McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, van Gils MJ, Euler Z, Burger JA, Seaman MS, Sanders RW, Schuitemaker H, Poignard P, Wrin T, Burton DR, Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLOS PATHOG 2015;11 (8):e1005110 [PubMed]
Pritchard LK, Vasiljevic S, Ozorowski G, Seabright GE, Cupo A, Ringe R, Kim HJ, Sanders RW, Doores KJ, Burton DR, Wilson IA, Ward AB, Moore JP, Crispin M, Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. CELL REP 2015;11 (10):1604-1613 [PubMed]
Pugach P, Ozorowski G, Cupo A, Ringe R, Yasmeen A, de Val N, Derking R, Kim HJ, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, Julien JP, Burton DR, Wilson IA, Sanders RW, Klasse PJ, Ward AB, Moore JP, A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J VIROL 2015;89 (6):3380-3395 [PubMed]
Ringe RP, Yasmeen A, Ozorowski G, Go EP, Pritchard LK, Guttman M, Ketas TA, Cottrell CA, Wilson IA, Sanders RW, Cupo A, Crispin M, Lee KK, Desaire H, Ward AB, Klasse PJ, Moore JP, Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. J VIROL 2015;89 (23):12189-12210 [PubMed]
Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, Labranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP, HIV-1 neutralizing antibodies induced by native-like envelope trimers. SCIENCE 2015;349 (6244):aac4223-154 [PubMed]
Sliepen K, Medina-Ramírez M, Yasmeen A, Moore JP, Klasse PJ, Sanders RW, Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. VIROLOGY 2015;486:116-120 [PubMed]
Sliepen K, Ozorowski G, Burger JA, van Montfort T, Stunnenberg M, Labranche C, Montefiori DC, Moore JP, Ward AB, Sanders RW, Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. RETROVIROLOGY 2015;12 (1):82 [PubMed]
Sliepen K, van Montfort T, Melchers M, Isik G, Sanders RW, Immunosilencing a highly immunogenic protein trimerization domain. J BIOL CHEM 2015;290 (12):7436-7442 [PubMed]
Sliepen K, van Montfort T, Ozorowski G, Pritchard LK, Crispin M, Ward AB, Sanders RW, Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer. BIOMOLECULES 2015;5 (4):2919-2934 [PubMed]
Stax MJ, Mouser EEIM, van Montfort T, Sanders RW, de Vries HJC, Dekker HL, Herrera C, Speijer D, Pollakis G, Paxton WA, Colorectal mucus binds DC-SIGN and inhibits HIV-1 trans-infection of CD4+ T-lymphocytes. PLOS ONE 2015;10 (3):e0122020 [PubMed]
van der Sluis RM, van Capel TMM, Speijer D, Sanders RW, Berkhout B, de Jong EC, Jeeninga RE, van Montfort T, Dendritic cell type-specific HIV-1 activation in effector T cells: implications for latent HIV-1 reservoir establishment. AIDS 2015;29 (9):1003-1014 [PubMed]
van Montfort T, Thomas AAM, Krawczyk PM, Berkhout B, Sanders RW, Paxton WA, Reactivation of Neutralized HIV-1 by Dendritic Cells Is Dependent on the Epitope Bound by the Antibody. J IMMUNOL 2015;195 (8):3759-3768 [PubMed]
Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Peña AT, Cupo A, Julien JP, van Gils M, Lee PS, Peng W, Paulson JC, Poignard P, Burton DR, Moore JP, Sanders RW, Wilson IA, Ward AB, Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. IMMUNITY 2014;40 (5):669-680 [PubMed]
Chung NPY, Matthews K, Kim HJ, Ketas TJ, Golabek M, de Los Reyes K, Korzun J, Yasmeen A, Sanders RW, Klasse PJ, Wilson IA, Ward AB, Marozsan AJ, Moore JP, Cupo A, Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. RETROVIROLOGY 2014;11 (1):33 [PubMed]
Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, Dekosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR, Becker J, Benjamin B, Blakesley R, Bouffard G, Brooks S, Coleman H, Dekhtyar M, Gregory M, Guan X, Gupta J, Han J, Hargrove A, Ho Sl, Johnson T, Legaspi R, Lovett S, Maduro Q, Masiello C, Maskeri B, McDowell J, Montemayor C, Mullikin J, Park M, Riebow N, Schandler K, Schmidt B, Sison C, Stantripop M, Thomas J, Thomas P, Vemulapalli M, Young A, Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. NATURE 2014;509 (7498):55-62 [PubMed]
Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang CH, McBride R, von Bredow B, Shivatare SS, Wu CY, Chan-Hui PY, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong CH, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR, Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. IMMUNITY 2014;40 (5):657-668 [PubMed]
Guttman M, Garcia NK, Cupo A, Matsui T, Julien JP, Sanders RW, Wilson IA, Moore JP, Lee KK, CD4-induced activation in a soluble HIV-1 Env trimer. STRUCTURE 2014;22 (7):974-984 [PubMed]
Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Imamichi H, Georgiev IS, Chuang GY, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, de la Peña AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M, Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. NATURE 2014;515 (7525):138-142 [PubMed]
Isik G. HIV-1 envelope glycoproteins with costimulatory domains for vaccine applications. S.l.: s.n.; 2014. 229p. ISBN 9789053358986 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Berkhout B; copromotor(s): Sanders RW)
Isik G, Sliepen K, van Montfort T, Sanders RW, Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL. PLOS ONE 2014;9 (9):e107683 [PubMed]
Isik G, van Montfort T, Chung NPY, Moore JP, Sanders RW, Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens. J IMMUNOL 2014;192 (10):4628-4635 [PubMed]
Medina-Ramírez M, Sanders RW, Klasse PJ, Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?. EXPERT REV VACCINES 2014;13 (4):449-452 [PubMed]
Sanders RW, Moore JP, HIV: A stamp on the envelope. NATURE 2014;514 (7523):437-438 [PubMed]
Sok D, van Gils MJ, Pauthner M, Julien JP, Saye-Francisco KL, Hsueh J, Briney B, Lee JH, Le KM, Lee PS, Hua Y, Seaman MS, Moore JP, Ward AB, Wilson IA, Sanders RW, Burton DR, Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. P NATL ACAD SCI USA 2014;111 (49):17624-17629 [PubMed]
van den Kerkhof TLGM, Euler Z, van Gils MJ, Boeser-Nunnink BD, Schuitemaker H, Sanders RW, Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers. AIDS 2014;28 (8):1237-1240 [PubMed]
van Gils MJ, Sanders RW, In vivo protection by broadly neutralizing HIV antibodies. TRENDS MICROBIOL 2014;22 (10):550-551 [PubMed]
Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, Ward AB, Wilson IA, Sanders RW, Moore JP, Klasse PJ, Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. RETROVIROLOGY 2014;11:41 [PubMed]
Yu F, Lu L, Liu Q, Yu X, Wang L, He E, Zou P, Du L, Sanders RW, Liu S, Jiang S, ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. BBA-BIOMEMBRANES 2014;1838 (5):1296-1305 [PubMed]
Baan E, de Ronde A, Stax M, Sanders RW, Luchters S, Vyankandondera J, Lange JM, Pollakis G, Paxton WA, HIV-1 autologous antibody neutralization associates with mother to child transmission. PLOS ONE 2013;8 (7):e69274 [PubMed]
Bontjer I, Melchers M, Tong T, van Montfort T, Eggink D, Montefiori D, Olson WC, Moore JP, Binley JM, Berkhout B, Sanders RW, Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers. PLOS ONE 2013;8 (6):e67484 [PubMed]
Hoorelbeke B, van Montfort T, Xue J, LiWang PJ, Tanaka H, Igarashi Y, van Damme EJM, Sanders RW, Balzarini J, HIV-1 envelope trimer has similar binding characteristics for carbohydrate-binding agents as monomeric gp120. FEBS LETT 2013;587 (7):860-866 [PubMed]
Isik G, Chung NPY, van Montfort T, Menis S, Matthews K, Schief WR, Moore JP, Sanders RW, An HIV-1 Envelope Glycoprotein Trimer with an Embedded IL-21 Domain Activates Human B Cells. PLOS ONE 2013;8 (6):e67309 [PubMed]
Isik G, van Montfort T, Boot M, Cobos Jiménez V, Kootstra NA, Sanders RW, Chimeric HIV-1 envelope glycoproteins with potent intrinsic granulocyte-macrophage colony-stimulating factor (GM-CSF) activity. PLOS ONE 2013;8 (4):e60126 [PubMed]
Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA, Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer. SCIENCE 2013;342 (6165):1477-1483 [PubMed]
Julien JP, Lee JH, Cupo A, Murin CD, Derking R, Hoffenberg S, Caulfield MJ, King CR, Marozsan AJ, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB, Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. P NATL ACAD SCI USA 2013;110 (11):213-218 [PubMed]
Julien JP, Sok D, Khayat R, Lee JH, Doores KJ, Walker LM, Ramos A, Diwanji DC, Pejchal R, Cupo A, Katpally U, Depetris RS, Stanfield RL, McBride R, Marozsan AJ, Paulson JC, Sanders RW, Moore JP, Burton DR, Poignard P, Ward AB, Wilson IA, Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLOS PATHOG 2013;9 (5):e1003342 [PubMed]
Khayat R, Lee JH, Julien JP, Cupo A, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB, Structural Characterization of Cleaved, Soluble HIV-1 Envelope Glycoprotein Trimers. J VIROL 2013;87 (17):9865-9872 [PubMed]
Klasse PJ, Depetris RS, Pejchal R, Julien JP, Khayat R, Lee JH, Marozsan AJ, Cupo A, Cocco N, Korzun J, Yasmeen A, Ward AB, Wilson IA, Sanders RW, Moore JP, Influences on Trimerization and Aggregation of Soluble, Cleaved HIV-1 SOSIP Envelope Glycoprotein. J VIROL 2013;87 (17):9873-9885 [PubMed]
Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA, Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. NAT STRUCT MOL BIOL 2013;20 (7):796-+ [PubMed]
Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB, Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer. SCIENCE 2013;342 (6165):1484-1490 [PubMed]
Malherbe DC, Sanders RW, van Gils MJ, Park B, Gomes MM, Schuitemaker H, Barnett S, Haigwood NL, HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans. PLOS ONE 2013;8 (9):e75277 [PubMed]
Matthews K, Chung NPY, Klasse PJ, Moutaftsi M, Carter D, Salazar AM, Reed SG, Sanders RW, Moore JP, Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells. PLOS ONE 2013;8 (5):e63785 [PubMed]
Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, Cupo A, Korzun J, Derking R, van Montfort T, Julien JP, Wilson IA, Klasse PJ, Ward AB, Moore JP, Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. P NATL ACAD SCI USA 2013;110 (45):18256-18261 [PubMed]
Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Peña AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP, A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLOS PATHOG 2013;9 (9):e1003618 [PubMed]
van den Kerkhof TLGM, Feenstra KA, Euler Z, van Gils MJ, Rijsdijk LWE, Boeser-Nunnink BD, Heringa J, Schuitemaker H, Sanders RW, HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. RETROVIROLOGY 2013;10 (1):102 [PubMed]
van der Sluis RM, van Montfort T, Centlivre M, Schopman NCT, Cornelissen M, Sanders RW, Berkhout B, Jeeninga RE, Paxton WA, Pollakis G, Quantitation of HIV-1 DNA with a sensitive TaqMan assay that has broad subtype specificity. J VIROL METHODS 2013;187 (1):94-102 [PubMed]
van der Sluis RM, van Montfort T, Pollakis G, Sanders RW, Speijer D, Berkhout B, Jeeninga RE, Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes. PLOS PATHOG 2013;9 (3):e1003259-(15 p.) [PubMed]
van Gils MJ, Sanders RW, Broadly neutralizing antibodies against HIV-1: templates for a vaccine. VIROLOGY 2013;435 (1):46-56 [PubMed]
Anastassopoulou CG, Ketas TJ, Sanders RW, Klasse PJ, Moore JP, Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. VIROLOGY 2012;428 (2):86-97 [PubMed]
Banerjee K, Michael E, Eggink D, van Montfort T, Lasnik AB, Palmer KE, Sanders RW, Moore JP, Klasse PJ, Occluding the Mannose Moieties on Human Immunodeficiency Virus Type 1 gp120 with Griffithsin Improves the Antibody Responses to Both Proteins in Mice. AIDS RES HUM RETROV 2012;28 (2):206-214 [PubMed]
Berkhout B, Eggink D, Sanders RW, Is there a future for antiviral fusion inhibitors?. CURR OPIN VIROL 2012;2 (1):50-59 [PubMed]
Berkhout B, Sanders RW, Gene therapy as a vaccine for HIV-1. EXPERT OPIN BIOL TH 2012;12 (10):1315-1321 [PubMed]
Berro R, Klasse PJ, Jakobsen MR, Gorry PR, Moore JP, Sanders RW, V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc. VIROLOGY 2012;427 (2):158-165 [PubMed]
Berro R, Klasse PJ, Jakobsen MR, Gorry PR, Moore JP, Sanders RW, V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc (vol 427, pg 158, 2012). VIROLOGY 2012;428 (1):76
Chung NPY, Matthews K, Klasse PJ, Sanders RW, Moore JP, HIV-1 gp120 Impairs the Induction of B Cell Responses by TLR9-Activated Plasmacytoid Dendritic Cells. J IMMUNOL 2012;189 (11):5257-5265 [PubMed]
Depetris RS, Julien JP, Khayat R, Lee JH, Pejchal R, Katpally U, Cocco N, Kachare M, Massi E, David KB, Cupo A, Marozsan AJ, Olson WC, Ward AB, Wilson IA, Sanders RW, Moore JP, Partial Enzymatic Deglycosylation Preserves the Structure of Cleaved Recombinant HIV-1 Envelope Glycoprotein Trimers. J BIOL CHEM 2012;287 (29):24239-24254 [PubMed]
de Vries RP, Smit CH, de Bruin E, Rigter A, de Vries E, Cornelissen LAHM, Eggink D, Chung NPY, Moore JP, Sanders RW, Hokke CH, Koopmans M, Rottier PJM, de Haan CAM, Glycan-Dependent Immunogenicity of Recombinant Soluble Trimeric Hemagglutinin. J VIROL 2012;86 (21):11735-11744 [PubMed]
Klasse PJ, Sanders RW, Cerutti A, Moore JP, How Can HIV-Type-1-Env Immunogenicity Be Improved to Facilitate Antibody-Based Vaccine Development?. AIDS RES HUM RETROV 2012;28 (1):1-15 [PubMed]
Matthews K, Chung NPY, Klasse PJ, Moore JP, Sanders RW, Potent Induction of Antibody-Secreting B Cells by Human Dermal-Derived CD14(+) Dendritic Cells Triggered by Dual TLR Ligation. J IMMUNOL 2012;189 (12):5729-5744 [PubMed]
Melchers M, Bontjer I, Tong T, Chung NPY, Klasse PJ, Eggink D, Montefiori DC, Gentile M, Cerutti A, Olson WC, Berkhout B, Binley JM, Moore JP, Sanders RW, Targeting HIV-1 Envelope Glycoprotein Trimers to B Cells by Using APRIL Improves Antibody Responses. J VIROL 2012;86 (5):2488-2500 [PubMed]
Sanders RW, HIV takes double hit before entry. BMC BIOL 2012;10 (1):99 [PubMed]
Schopman NCT, van Montfort T, Willemsen M, Knoepfel SA, Pollakis G, van Kampen A, Sanders RW, Haasnoot J, Berkhout B, Selective packaging of cellular miRNAs in HIV-1 particles. VIRUS RES 2012;169 (2):438-447 [PubMed]
van Montfort T, Sanders RW, Optimizing cellular immunity against HIV-1 Gag and preventing suppression by HIV-1 gp120. EXPERT REV VACCINES 2012;11 (10):1175-1177 [PubMed]
Berkhout B, Sanders RW, Molecular strategies to design an escape-proof antiviral therapy. ANTIVIR RES 2011;92 (1):7-14 [PubMed]
Berro R, Klasse PJ, Lascano D, Flegler A, Nagashima KA, Sanders RW, Sakmar TP, Hope TJ, Moore JP, Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J VIROL 2011;85 (16):8227-8240 [PubMed]
Eggink D, Bontjer I, Langedijk JPM, Berkhout B, Sanders RW, Resistance of Human Immunodeficiency Virus Type 1 to a Third-Generation Fusion Inhibitor Requires Multiple Mutations in gp41 and Is Accompanied by a Dramatic Loss of gp41 Function. J VIROL 2011;85 (20):10785-10797 [PubMed]
Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YK, Depetris R, Marozsan AJ, Sanders RW, Klasse PJ, Milne JLS, Wilson IA, Olson WC, Moore JP, Subramaniam S, Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. P NATL ACAD SCI USA 2011;108 (28):11440-11445 [PubMed]
Melchers M, Matthews K, de Vries RP, Eggink D, van Montfort T, Bontjer I, van de Sandt C, David K, Berkhout B, Moore JP, Sanders RW, A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. RETROVIROLOGY 2011;8 (1):48 [PubMed]
Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA, A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. SCIENCE 2011;334 (6059):1097-1103 [PubMed]
Sanders RW, Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine. EXPERT REV VACCINES 2011;10 (8):1117-1120 [PubMed]
van Montfort T, Eggink D, Boot M, Tuen M, Hioe CE, Berkhout B, Sanders RW, HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation. J IMMUNOL 2011;187 (9):4676-4685 [PubMed]
van Montfort T, Melchers M, Isik G, Menis S, Huang PS, Matthews K, Michael E, Berkhout B, Schief WR, Moore JP, Sanders RW, A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses. J BIOL CHEM 2011;286 (25):22250-22261 [PubMed]
Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP, IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS RES HUM RETROV 2010;26 (4):445-458 [PubMed]
Binley JM, Ban YEA, Crooks ET, Eggink D, Osawa K, Schief WR, Sanders RW, Role of Complex Carbohydrates in Human Immunodeficiency Virus Type 1 Infection and Resistance to Antibody Neutralization. J VIROL 2010;84 (11):5637-5655 [PubMed]
Bontjer I, Melchers M, Eggink D, David K, Moore JP, Berkhout B, Sanders RW, Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. J BIOL CHEM 2010;285 (47):36456-36470 [PubMed]
Eggink D, Berkhout B, Sanders RW, Inhibition of HIV-1 by Fusion Inhibitors. CURR PHARM DESIGN 2010;16 (33):3716-3728 [PubMed]
Eggink D, Melchers M, Wuhrer M, van Montfort T, dey AK, Naaijkens BA, David KB, Le Douce V, Deelder AM, Kang K, Olson WC, Berkhout B, Hokke CH, Moore JP, Sanders RW, Corrigendum to: Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function (vol 401, pg 236, 2010). VIROLOGY 2010;406 (1):162-163
Eggink D, Melchers M, Wuhrer M, van Montfort T, dey AK, Naaijkens BA, David KB, Le Douce V, Deelder AM, Kang K, Olson WC, Berkhout B, Hokke CH, Moore JP, Sanders RW, Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. VIROLOGY 2010;401 (2):236-247 [PubMed]
Eggink WD. Resistance to HIV-1 fusion inhibitors. s.l.: s.n.; 2010. 225p. ISBN 9789490371289 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Berkhout B; copromotor(s): Sanders RW)
Melchers M. Improving HIV-1 enveloppe glycoprotein vaccines. s.l.: s.n.; 2010. 205p. ISBN 9789490371517 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Berkhout B; copromotor(s): Sanders RW)
Sanders RW, Berkhout B, Sealing the Envelope - The HIV-1 Envelope Glycoproteins as Targets for Therapeutics and Vaccines. CURR PHARM DESIGN 2010;16 (33):3699-3700 [PubMed]
Banerjee K, Andjelic S, Klasse PJ, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP, Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. VIROLOGY 2009;389 (1-2):108-121 [PubMed]
Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP, Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLOS PATHOG 2009;5 (8):e1000548 [PubMed]
Bontjer I, Land A, Eggink D, Verkade E, Tuin K, Baldwin C, Pollakis G, Paxton WA, Braakman I, Berkhout B, Sanders RW, Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J VIROL 2009;83 (1):368-383 [PubMed]
de Jong MD, Sanders RW, The future of influenza vaccines. BMJ-BRIT MED J 2009;339:b4014 [PubMed]
Eggink D, Langedijk JPM, Bonvin AMJJ, Deng Y, Lu M, Berkhout B, Sanders RW, Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J BIOL CHEM 2009;284 (39):26941-26950 [PubMed]
Stax MJ, van Montfort T, Sprenger RR, Melchers M, Sanders RW, van Leeuwen E, Repping S, Pollakis G, Speijer D, Paxton WA, Mucin 6 in seminal plasma binds DC-SIGN and potently blocks dendritic cell mediated transfer of HIV-1 to CD4(+) T-lymphocytes. VIROLOGY 2009;391 (2):203-211 [PubMed]
Xu W, Santini PA, Sullivan JS, He B, Shan M, Ball SC, Dyer WB, Ketas TJ, Chadburn A, Cohen-Gould L, Knowles DM, Chiu A, Sanders RW, Chen K, Cerutti A, HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. NAT IMMUNOL 2009;10 (9):1008-1017 [PubMed]
Eggink D, Baldwin CE, Deng Y, Langedijk JPM, Lu M, Sanders RW, Berkhout B, Selection of T1249-resistant human immunodeficiency virus type 1 variants. J VIROL 2008;82 (13):6678-6688 [PubMed]
Sanders RW, Hsu STD, van Anken E, Liscaljet IM, Dankers M, Bontjer I, Land A, Braakman I, Bonvin AMJJ, Berkhout B, Evolution rescues folding of human immunodeficiency virus-1 envelope glycoprotein GP120 lacking a conserved disulfide bond. MOL BIOL CELL 2008;19 (11):4707-4716 [PubMed]
Sanders RW, van Anken E, Nabatov AA, Liscaljet IM, Bontjer I, Eggink D, Melchers M, Busser E, Dankers MM, Groot F, Braakman I, Berkhout B, Paxton WA, The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. RETROVIROLOGY 2008;5:10 [PubMed]
van Anken E, Sanders RW, Liscaljet IM, Land A, Bontjer I, Tillemans S, Nabatov AA, Paxton WA, Berkhout B, Braakman I, Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein. MOL BIOL CELL 2008;19 (10):4298-4309 [PubMed]
Eggink D, Melchers M, Sanders RW, Antibodies to HIV-1: aiming at the right target. TRENDS MICROBIOL 2007;15 (7):291-294 [PubMed]
Shan M, Klasse PJ, Banerjee K, dey AK, Iyer SPN, Dionisio R, Charles D, Campbell-Gardener L, Olson WC, Sanders RW, Moore JP, HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLOS PATHOG 2007;3 (11):e169-1650 [PubMed]
Groot F, Sanders RW, ter Brake O, Nazmi K, Veerman ECI, Bolscher JGM, Berkhout B, Histatin 5-derived peptide with improved fungicidal properties enhances human immunodeficiency virus type 1 replication by promoting viral entry. J VIROL 2006;80 (18):9236-9243 [PubMed]
Beddows S, Schülke N, Kirschner M, Barnes K, Franti M, Michael E, Ketas T, Sanders RW, Maddon PJ, Olson WC, Moore JP, Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J VIROL 2005;79 (14):8812-8827 [PubMed]
Fernández A, Tawfik DS, Berkhout B, Sanders R, Kloczkowski A, Sen T, Jernigan B, Protein promiscuity: drug resistance and native functions--HIV-1 case. J BIOMOL STRUCT DYN 2005;22 (6):615-624 [PubMed]
Groot F, Geijtenbeek TBH, Sanders RW, Baldwin CE, Sanchez-Hernandez M, Floris R, van Kooyk Y, de Jong EC, Berkhout B, Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. J VIROL 2005;79 (5):3009-3015 [PubMed]
Baldwin CE, Sanders RW, Deng Y, Jurriaans S, Lange JM, Lu M, Berkhout B, Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J VIROL 2004;78 (22):12428-12437 [PubMed]
Sanders RW. The HIV-1 envelope glycoproteins: folding, function and vaccine design. S.l.: s.n.; 2004. 337p. ISBN 90 5356 667 8 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Berkhout B, Moore JP; copromotor(s): )
Sanders RW, Busser E, Moore JP, Lu M, Berkhout B, Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS RES HUM RETROV 2004;20 (7):742-749 [PubMed]
Sanders RW, Dankers MM, Busser E, Caffrey M, Moore JP, Berkhout B, Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41. RETROVIROLOGY 2004;1 (1):3 [PubMed]
Baldwin CE, Sanders RW, Berkhout B, Inhibiting HIV-1 entry with fusion inhibitors. CURR MED CHEM 2003;10 (17):1633-1642 [PubMed]
Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, Schiffner L, Travis B, Kuhmann S, Burton DR, Hu SL, Olson WC, Moore JP, Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J VIROL 2002;76 (6):2606-2616 [PubMed]
Sanders RW, de Jong EC, Baldwin CE, Schuitemaker JHN, Kapsenberg ML, Berkhout B, Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J VIROL 2002;76 (15):7812-7821 [PubMed]
Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP, The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J VIROL 2002;76 (14):7293-7305 [PubMed]
Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, Paluch M, Berkhout B, Maddon PJ, Olson WC, Lu M, Moore JP, Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J VIROL 2002;76 (17):8875-8889 [PubMed]
Schülke N, Vesanen MS, Sanders RW, Zhu P, Lu M, Anselma DJ, Villa AR, Parren PWHI, Binley JM, Roux KH, Maddon PJ, Moore JP, Olson WC, Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J VIROL 2002;76 (15):7760-7776 [PubMed]
Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B, Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect. VIROLOGY 2001;283 (2):294-305 [PubMed]
Binley JM, Sanders RW, Clas B, Schuelke N, Master A, Guo Y, Kajumo F, Anselma DJ, Maddon PJ, Olson WC, Moore JP, A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J VIROL 2000;74 (2):627-643 [PubMed]
Sanders RW, Schiffner L, Master A, Kajumo F, Guo Y, Dragic T, Moore JP, Binley JM, Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J VIROL 2000;74 (11):5091-5100 [PubMed]
Verhoef K, Sanders RW, Fontaine V, Kitajima S, Berkhout B, Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by conversion of an NF-kappaB enhancer element into a GABP binding site. J VIROL 1999;73 (2):1331-1340 [PubMed]
Key publications

de Taeye SW, Ozorowski G, Torrents de la Peña A, Guttman M, Julien JP, van den Kerkhof TLGM, Burger JA, Pritchard LK, Pugach P, Yasmeen A, Crampton J, Hu J, Bontjer I, Torres JL, Arendt H, DeStefano J, Koff WC, Schuitemaker H, Eggink D, Berkhout B, Dean H, Labranche C, Crotty S, Crispin M, Montefiori DC, Klasse PJ, Lee KK, Moore JP, Wilson IA, Ward AB, Sanders RW, Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. CELL 2015;163 (7):1702-1715 [PubMed]
Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, Labranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP, HIV-1 neutralizing antibodies induced by native-like envelope trimers. SCIENCE 2015;349 (6244):aac4223-154 [PubMed]
van Gils MJ, van den Kerkhof TLGM, Ozorowski G, Cottrell CA, Sok D, Pauthner M, Pallesen J, de Val N, Yasmeen A, de Taeye SW, Schorcht A, Gumbs S, Johanna I, Saye-Francisco K, Liang CH, Landais E, Nie X, Pritchard LK, Crispin M, Kelsoe G, Wilson IA, Schuitemaker H, Klasse PJ, Moore JP, Burton DR, Ward AB, Sanders RW, An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. NAT MICROBIOL 2017;2 (2):16199 [PubMed]
Sanders RW, Moore JP, HIV: A stamp on the envelope. NATURE 2014;514 (7523):437-438 [PubMed]


All Publications

Research programmes

HIV vaccine research aimed at the induction of neutralizing antibodies

We study the HIV-1 envelope protein complex (Env), the protein that is required for the induction of humoral immunity. Specifically we modify the protein in order to improve the induction of neutralizing antibodies.

Faculty
Prof. dr. R.W. Sanders (Weill Medical College of Cornell University)

Postdocs
Dr. M.J. van Gils
Dr. M. Medina-Ramirez
Dr. K.H. Sliepen

PhD Students
P.J.M. Brouwer
A.L. Chumbe Mendoza MSc
M.M. van Haaren
I. del Moral Sanchez
J. van Schooten
A. Schorcht MSc
A. Torrents de la Peña

Others
T.P.L. Bijl BSc
Ing. I. Bontjer
Dr. M.J. van Breemen
Ing. J.A. Burger
P. van der Woude BA

Other research related activities
  • (part-time) outside employment, Weill Medical College of Cornell University
  • Membership of advisory board / Consultant, Crucell
Current research funding
  • AMC
  • AMC (Vrijgesteld)
  • amfAR
  • Europese Unie
  • FONDATION DORMEUR
  • Janssen Vaccines & Prevention B.V.
  • Joan and Sanford I. Weill Medical Coll. of Cornell Univ.
  • K.N.A.W.
  • Stichting Aidsfonds/SOA AIDS Nederland
  • Stichting AMC Foundation (Vrijgesteld)
  • University of Washington